Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab

ZOL combined with BEV did not predispose to ONJ participants with cancer that had metastasized to the bone who underwent a baseline dental examination and preventive dental measures. The study results must be considered in the context of the study's protocols and the follow-up period.